WEST LAFAYETTE, Indiana — Biotech firm Kylin Therapeutics is looking to raise $2 million to help it develop technology that “turns off” certain disease-causing genes.
The company has sold about $58,000 of its $2 million offering, according to a regulatory filing.
Chief Executive Eric Davis didn’t return a call.
How Artera is Using Agentic AI to Humanize Patient Care
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Kylin’s technology is based on what’s known as RNA interference, a technique for “gene silencing.” Essentially, interference RNAs are introduced into a cell to prevent the expression of genes that cause harmful diseases such as cancer or AIDS. RNA is the abbreviation for ribonucleic acid, a molecule that carries out DNA’s instructions for making proteins.
In 2007, Kylin struck a partnership with a division of drugmaker Wyeth to develop cancer therapeutics for animals. In January 2009, the company announced that it had received a $1.2 million grant from the state of Indiana.
Kylin is backed by North Carolina-based Golden Pine Ventures and Indiana-based In-vivo Ventures. Kylin’s chief executive, Davis, founded In-vivo.
Two researchers won the 2006 Nobel prize for medicine or physiology for their work investigating RNA interference.